- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
FDA to issue proposed rule for certain OTC shampoos
The FDA is issuing a proposed rule to amend the final monograph (FM) for OTC dandruff, seborrheic dermatitis, and psoriasis drug products to include the combination of 1.8% coal tar solution and 1.5% menthol in a shampoo drug product to control dandruff. The agency is issuing this proposed rule after considering information submitted in a citizen petition. In 1993, FDA received a petition to amend the FM for OTC dandruff, seborrheic dermatitis, and psoriasis drug products to include the combination of 9% coal tar solution and 1.5% menthol in a shampoo drug product to relieve scalp itching associated with dandruff. To submit electronic comments by March 9, 2006, visit http://www.regulations.gov/.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
